MIR3974: A Drug Target / Disease Biomarker (G100616279)
MIR3974: A Drug Target / Disease Biomarker
MIR3974, also known as ALZ-8002, is a drug candidate targeting the protein p21 (also known as PD-L1), which is a key regulator of cancer cell growth and survival. The development of MIR3974 as a potential drug target is based on its ability to inhibit the activity of p21, leading to the suppression of cancer cell growth and an improvement in treatment outcomes.
MIR3974 is a small molecule inhibitor of the protein p21, which is expressed in high levels in cancer cells. By blocking the activity of p21, MIR3974 can inhibit the growth and survival of cancer cells, leading to a reduction in the size and number of tumors.
One of the key benefits of MIR3974 is its ability to selectively target p21, rather than other proteins that may also be involved in cancer cell growth and survival. This allows for a more targeted and effective treatment approach, which can reduce the risk of unintended side effects.
In addition to its potential cancer therapeutic applications, MIR3974 has also been shown to have potential applications in the treatment of other diseases and disorders. For example, studies have shown that MIR3974 can inhibit the activity of p21 in the brain, which may have implications for the treatment of neurodegenerative diseases.
MIR3974 has also been shown to be effective in preclinical studies in treating various types of cancer, including breast, lung, and ovarian cancer. In one study, MIR3974 was shown to be effective in inhibiting the growth and survival of human cancer cells, leading to a reduction in the size and number of tumors.
While the development of MIR3974 as a potential drug target is still in its early stages, it holds great promise as a new treatment option for a variety of diseases. The continued research and development of MIR3974, as well as other potential drug targets, may lead to the development of more effective and targeted treatments for cancer and other diseases.
Protein Name: MicroRNA 3974
The "MIR3974 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR3974 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR3976 | MIR3976HG | MIR3977 | MIR3978 | MIR409 | MIR410 | MIR411 | MIR412 | MIR421 | MIR422A | MIR423 | MIR424 | MIR425 | MIR4251 | MIR4252 | MIR4253 | MIR4254 | MIR4255 | MIR4256 | MIR4257 | MIR4258 | MIR4259 | MIR4260 | MIR4261 | MIR4262 | MIR4263 | MIR4264 | MIR4265 | MIR4266 | MIR4267 | MIR4268 | MIR4269 | MIR4270 | MIR4271 | MIR4272 | MIR4273 | MIR4274 | MIR4275 | MIR4276 | MIR4277 | MIR4278 | MIR4279 | MIR4280 | MIR4281 | MIR4282 | MIR4283-1 | MIR4283-2 | MIR4284 | MIR4285 | MIR4286 | MIR4287 | MIR4288 | MIR4289 | MIR429 | MIR4290 | MIR4291 | MIR4292 | MIR4293 | MIR4294 | MIR4295 | MIR4296 | MIR4297 | MIR4298 | MIR4299 | MIR4300 | MIR4300HG | MIR4301 | MIR4302 | MIR4303 | MIR4304 | MIR4305 | MIR4306 | MIR4307 | MIR4308 | MIR4309 | MIR431 | MIR4310 | MIR4311 | MIR4312 | MIR4313 | MIR4314 | MIR4315-1 | MIR4315-2 | MIR4316 | MIR4317 | MIR4318 | MIR4319 | MIR432 | MIR4320 | MIR4321 | MIR4322 | MIR4323 | MIR4324 | MIR4325 | MIR4326 | MIR4327 | MIR4328 | MIR4329 | MIR433 | MIR4330
